DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

Information source: University of Colorado, Denver
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Open Angle Glaucoma; Ocular Hypertension; Pigment Dispersion Syndrome; Pseudoexfoliation Glaucoma

Phase: N/A

Status: Recruiting

Sponsored by: University of Colorado, Denver

Official(s) and/or principal investigator(s):
Malik Y Kahook, MD, Principal Investigator, Affiliation: University of Colorado, Denver

Overall contact:
Mary Preston, Phone: 720-848-2035, Email: Mary.preston@ucdenver.edu


The purpose of this research study is to hypothesize that Simbrinza will achieve a decrease in intraocular pressure and increase in ocular perfusion pressure throughout the diurnal and nocturnal periods. The primary aim of this study will be to determine the effects of Simbrinza at multiple intervals throughout a 24-hour period. The secondary aim will be to compare these to those of timolol.

Clinical Details

Official title: The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Intraocular pressure

Secondary outcome: Intraocular pressure

Detailed description: Intraocular pressure (IOP) is a major risk factor for the development of glaucoma. In addition, it is the only modifiable factor in the prevention and subsequent treatment of glaucomatous optic neuropathy. Most clinicians only have access to a single IOP measurement during a patient visit that may only occur once every four months. These snapshots in time are probably not adequate for the optimal management of glaucoma. Diurnal IOP curves can provide a better estimate of each patient's individual IOP variation throughout the day. However diurnal curves do not typically cover another crucial time, the nocturnal period. Glaucomatous eyes have been shown to have different IOP curves during the nocturnal period compared to healthy controls. In addition, different classes of glaucoma drugs have variable IOP lowering effects during the nocturnal hours compared to the diurnal/wake period. For example, the betablocker timolol was shown to lower IOP during daytime hours but failed to lower IOP during the nocturnal period in the habitual position. Similarly, the alpha-agonist brimonidine failed to lower IOP overnight after significantly lowering IOP during the diurnal period. On the other hand, the prostaglandin analogues, including latanoprost and travoprost, lowered IOP throughout the diurnal and nocturnal periods although nocturnal lowering appears less than the daytime hours. Therefore it is crucial to determine an accurate IOP curve for each form of medication during both wake and sleep hours.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Diagnosis of open angle glaucoma or ocular hypertension including pigment

dispersion glaucoma and pseudoexfoliation glaucoma.

- Age ≥ 18 years, of either gender, or any race/ethnicity

Exclusion Criteria:

- Females who are currently pregnant or planning to become pregnant during the study


- Contraindications to beta blockers (see below)

- Patients currently taking oral beta blocker therapy

- Diagnosis of any other form of glaucoma other than open-angle

- Schaffer angle grade < 2 in either eye by gonioscopy

- Intraocular surgery within 6 months or laser within 3 months

- Inability to safely discontinue all ocular medications for 6 weeks

- Patients who smoke or have irregular daily sleep patterns

- History of allergy or intolerance to topical carbonic anhydrase inhibitors, or


- Patients who have started or changed glucocorticoids therapy in the last 3 months

- Patients who are currently using medical or recreational marijuana

- Any use of a non-FDA approved medication for glaucoma in the last 3 months

Locations and Contacts

Mary Preston, Phone: 720-848-2035, Email: Mary.preston@ucdenver.edu

University of Colorado Eye Center, Aurora, Colorado 80045, United States; Recruiting
Mary Preston, Phone: 720-848-2035, Email: Mary.preston@ucdenver.edu
Steve Cho, Phone: 720-848-5050, Email: steve.cho@ucdenver.edu
Malik Y Kahook, MD, Principal Investigator
Additional Information

Starting date: August 2014
Last updated: August 6, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017